Gene · 970
NIH grants2,135
NIH grants whose papers are about the gene, through NIH's grant-paper links.
461 to 480 of 2,135
Download this page as JSON| Grant | Title | CD70 papers | Newest fiscal year |
|---|---|---|---|
| R01DK105821 | APOL1 associated disease spectrum | 2 | 2024 |
| R01GM143243 | MusIC: A multi-scale technology for integrating dynamic cellular function and molecular profiles | 2 | 2024 |
| T32ES007062 | Environmental Toxicology and Epidemiology Pre- and Post-Doctoral Research T32 Training Program | 2 | 2024 |
| T32GM007267 | Medical Scientist Training Program | 2 | 2024 |
| T32GM008244 | Medical Scientist Training Program | 2 | 2024 |
| U19AI067773 | Center for High-Throughput Minimally-Invasive Radiation Biodosimetry | 2 | 2024 |
| ZIABC011714 | Translational Immunology | 2 | 2024 |
| F31AI172078 | Defining signals contributing to inflammatory hemophagocyte differentiation in TLR7 mediated Macrophage Activation Syndrome | 1 | 2024 |
| F32CA271812 | Multi-functional cellular therapies to overcome tumor heterogeneity and limit toxicity in acute myeloid leukemia | 1 | 2024 |
| I01BX002195 | Immunological Memory of Obesity | 1 | 2024 |
| I01BX004903 | Rational Combination of MAP4K4 Inhibition and Immunotherapy in Pancreatic Cancer | 1 | 2024 |
| I01BX004935 | Restoring the Regulation of a Central Signaling Pathway to Prevent Metastases and Reinstate Tumor Immunity | 1 | 2024 |
| IK2CX002095 | Identifying Biomarkers of Post-traumatic Stress Disorder in U.S. Veterans using an Integrative Multi-Omics Approach | 1 | 2024 |
| K08CA230190 | Improving targeted therapy in FLT3-mutated AML | 1 | 2024 |
| K12CA001727 | City of Hope Clinical Oncology Career Research Development Program | 1 | 2024 |
| K22CA262343 | Elucidating the role of Ybx1 in cerebellar development and medulloblastoma | 1 | 2024 |
| OT2OD025276 | PRIDEnet for the All of Us Research Program | 1 | 2024 |
| P01CA093900 | The Biology of Prostate Cancer Skeletal Metastases | 1 | 2024 |
| P01CA250972 | Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response | 1 | 2024 |
| P20GM109005 | Center for Studies of Host Response to Cancer Therapy | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/grants?page=24